360° SearchNetwork Hot Spots Trends Time Series

Advanced Search Options >>

Medivation Inc

Type: Company

Name: Medivation Inc

First reported 21 hours ago - Updated 21 hours ago - 1 reports

UBS AG

Medivation Inc. Presents at UBS Global Healthcare Conference May202013 0100 PM

100 pm ET ExecutivesDavid T. Hung Chief Executive Officer President and Executive Director AnalystsMatthew Roden UBS Investment Bank Research Division Presentation Matthew Roden UBS Investment Bank Research DivisionG... ... [Published BioPortfolio - 21 hours ago]

Entities: Medivation Inc, Healthcare Conference, UBS AG

First reported May 21 2013 - Updated May 21 2013 - 1 reports

Medivation Shares Climbing Higher, Up 2...

One of today's notable stocks on the rise is Medivation (NASDAQ:MDVN), up 2.9% to $53.66. The S&P is trading 1,416 and the Dow is trading 13,026. Medivation (NASDAQ:MDVN) has potential upside of 30.1% based on a current price of $53.66 and analysts' consensus ... [Published Financial News Network online - May 21 2013]

Entities: Medivation Inc, Stocks, Moving Average

First reported May 20 2013 - Updated May 20 2013 - 1 reports

Medivation, Inc. Presents at UBS Global Healthcare Conference, May-20-2013 01:00 PM

Matthew Roden - UBS Investment Bank, Research DivisionGood afternoon, everyone. My name is Matt Roden. I'm one the biopic analysts here at UBS. I'd like to thank everyone for attending the new UBS Global Healthcare Conference. I'm pleased and privileged ... [Published Seeking Alpha - May 20 2013]

Entities: Xtandi, Patient, Placebo, Medivation Inc

First reported May 20 2013 - Updated May 20 2013 - 1 reports

Earnings Flashback: Since Reporting Quarterly Results 1 Week Ago Medivation Is Down 9.0% (MDVN)

(Comtex SmarTrend(R)) A week ago on May 9th, 2013 Medivation (NASDAQ:MDVN) reported earnings and analysts, on average, expected a loss of $0.40 on sales of $40.2 million. Medivation actually reported a loss of $0.36 per share on sales of $46.2 million, ... [Published Individual.com - May 20 2013]

Entities: Medivation Inc, Comtex

First reported May 19 2013 - Updated May 19 2013 - 1 reports

Aegerion Pharmaceuticals Inc

The Best- And Worst- Performing Biotech Stocks, May 10 To May 17

These are the best and worst-performing medical and biotech stocks from May 10 to May 17, 2013. This screen includes biotechnology and medical companies traded on the New York Stock Exchange, the Nasdaq or the American Stock Exchange that had market capitalizations ... [Published Forbes.com - May 19 2013]

Entities: Biotechnology, Stocks, Aegerion Pharmaceuticals Inc

First reported May 19 2013 - Updated May 19 2013 - 1 reports

Medivation Earnings In Retrospect: Down...

9 days ago, on May 9th, 2013, Medivation (NASDAQ:MDVN) reported its earnings. Analysts, on average, expected a loss of $0.40 per share on sales of $40.2 million. The company actually reported a loss of $0.36 per share on sales of $46.2 million, beating ... [Published Financial News Network online - May 19 2013]

Entities: Medivation Inc, Stocks, Moving Average

First reported May 18 2013 - Updated May 18 2013 - 1 reports

Medivation Earnings In Retrospect: Down 9.0% in the Last 9 Days (MDVN)

(Financial News Network On) 9 days ago, on May 9th, 2013, Medivation (NASDAQ:MDVN) reported its earnings. Analysts, on average, expected a loss of $0.40 per share on sales of $40.2 million. The company actually reported a loss of $0.36 per share on ... [Published Individual.com - May 18 2013]

Entities: Medivation Inc

First reported May 17 2013 - Updated May 17 2013 - 1 reports

NASDAQ Decliners Watch List: Medivation, Inc. (NASDAQ:MDVN) and Theravance Inc. (NASDAQ:THRX) Added to Growing Stock Report's NASDAQ Decliners Watch List.

New York, NY -- (SBWIRE) -- 05/17/2013 -- Growing Stock Report expands its NASDAQ Decliners Weekly Watch List adding Medivation, Inc. (NASDAQ:MDVN) and Theravance Inc. (NASDAQ:THRX).Medivation, Inc. (NASDAQ:MDVN) a biopharmaceutical company that focuses ... [Published SBWire - May 17 2013]

Entities: Watch List, Theravance Inc, Medivation Inc

First reported May 17 2013 - Updated May 17 2013 - 1 reports

Third Rock Ventures adds biotech veterans to team

Third Rock Ventures has brought on Alnylam Pharmaceuticals ($ALNY) CEO John Maraganore in the advisory role of venture partner and former Genzyme and Sanofi ($SNY) executive James Geraghty as an entrepreneur-in-residence to support Third Rock's investments ... [Published FierceBiotech - May 17 2013]

Entities: Third Rock Ventures, Biotechnology, John Leonard

First reported May 17 2013 - Updated May 17 2013 - 1 reports

Shares of InterMune Rank the Highest in...

Below are the top five companies in the Biotechnology industry as measured by relative performance. This analysis was compiled based on yesterday's trading activity as we search for stocks that have the potential to outperform.InterMune (NASDAQ:ITMN) ... [Published Financial News Network online - May 17 2013]

Entities: InterMune Inc, Stocks, EXACT Sciences Corp, Cepheid

First reported May 15 2013 - Updated May 16 2013 - 2 reports

Bayer's radiation prostate cancer drug bags US nod

US regulators have approved Bayer's Xofigo as a treatment for prostate cancer, just three months after it was assigned a priority review.The US Food and Drug Administration has issued a green light for the injection for use in men with symptomatic late-stage ... [Published Pharma Times - May 16 2013]

Entities: Prostate Cancer, antineoplastic, Radiation

First reported May 16 2013 - Updated May 16 2013 - 1 reports

Tokai Pharma Raises $35.5M Series E Round for Prostate Cancer Clinical Studies

(c) 2013 Dow Jones & Company, Inc.Venture investors are fueling Tokai Pharmaceuticals Inc . with $35.5 million in Series E financing as the company strives to add to a growing list of new treatment options for prostate cancer.On Wednesday, the Food and ... [Published Dow Jones Financial Information Services - May 16 2013]

Entities: Tokai Pharmaceuticals Inc, Prostate Cancer, Xtandi, Medivation Inc

Quotes

"It is encouraging to have a new treatment for men with castration-resistant prostate cancer who are dealing with bone metastases. Xofigo provides another new option to treat this cancer using a different approach" Jan Manarite, senior educational facilitator for the Prostate Cancer Research Institute, said in the statement

Bayer Prostate Cancer Drug Gains FDA Approval [Published Genetic Engineering News - May 16 2013]

...approval of Medivation/Astellas Xtandi in August 2012, Xofigo is now the second prostate cancercancer drug approved in the US in the past year "that demonstrates an ability to extend the survival of men with metastatic prostate cancer”."

Bayer's radiation prostate cancer drug bags US nod [Published Pharma Times - May 16 2013]

"Most men with castration-resistant prostate cancer develop bone metastases, which can decrease overall survival" said Oliver Sartor, MD, North American Principal Investigator for the pivotal trial and medical director of the Tulane Cancer Center

Advanced Prostate Cancer Rx Approved [Published Daily Rx - May 16 2013]

...said Richard Pazdur, M D , director of the Office of Hematology and Oncology Products in the FDA's CenterCenter for Drug Evaluation and Research. "Xofigo is the second prostate cancercancer drug approved by the FDA in the past year that demonstrates an ability to extend the survival of men with metastatic prostate cancer."

FDA Approves New Drug for Advanced Prostate Cancer [Published HealthNewsDigest.com - May 15 2013]

More Content

sort by: Date \| Relevance
Medivation Inc. Presents at UBS Global Healthca... [Published BioPortfolio - 21 hours ago]
Medivation Shares Climbing Higher, Up 2... [Published Financial News Network online - May 21 2013]
Medivation, Inc. Presents at UBS Global Healthc... [Published Seeking Alpha - May 20 2013]
Earnings Flashback: Since Reporting Quarterly R... [Published Individual.com - May 20 2013]
Consensus Outlook: Prostate Cancer- Competition... [Published PipelineReview - May 20 2013]
KOL Insight: Prostate Cancer: Competition inten... [Published PipelineReview - May 20 2013]
The Best- And Worst- Performing Biotech Stocks,... [Published Forbes.com - May 19 2013]
Medivation Earnings In Retrospect: Down... [Published Financial News Network online - May 19 2013]
Medivation Earnings In Retrospect: Down 9.0% in... [Published Individual.com - May 18 2013]
Xtandi- The Real Potential and the Astellas Par... [Published TransWorldNews - May 18 2013]
Xofigo Approval Keeps the Ball Rolling For Baye... [Published Pharmaceutical Executive - May 18 2013]
NASDAQ Decliners Watch List: Medivation, Inc. (... [Published SBWire - May 17 2013]
Third Rock Ventures adds biotech veterans to team [Published FierceBiotech - May 17 2013]
Secondary Hormone Therapy for Castration-Resist... [Published Consultant Live - May 17 2013]
Shares of InterMune Rank the Highest in... [Published Financial News Network online - May 17 2013]
Bayer’s Xofigo wins FDA approval for treatment ... [Published Drugtopics.com - May 17 2013]
Bayer's Xofigo Cleared in the US Zacks [Published Yahoo! Finance - May 16 2013]
FDA Approves Radium Drug Xofigo for Metastatic ... [Published P&T Community - May 16 2013]
Bayer Prostate Cancer Drug Gains FDA Approval [Published Genetic Engineering News - May 16 2013]
FDA clears Bayer/ Algeta's prostate cancer radi... [Published PMLive - May 16 2013]
Bayer's radiation prostate cancer drug bags US nod [Published Pharma Times - May 16 2013]
Advanced Prostate Cancer Rx Approved [Published Daily Rx - May 16 2013]
Tokai Pharma Raises $35.5M Series E Round for P... [Published Dow Jones Financial Information Services - May 16 2013]
FDA Approves New Drug for Advanced Prostate Cancer [Published HealthNewsDigest.com - May 15 2013]
FDA approves new prostate cancer drug [Published Drug Store News - May 15 2013]
FDA Approves Bayer's Prostate Cancer Drug Three... [Published RTTNews.com - May 15 2013]
Bayer, Algeta Win U.S. Approval for Prostate Ca... [Published Bloomberg - May 15 2013]
FDA OKs pinpoint prostate cancer radiation drug... [Published FierceBiotech - May 15 2013]
FDA approves new drug for advanced prostate cancer [Published Noodls - May 15 2013]
Tokai lands $35M venture round for triple-threa... [Published FierceBiotech - May 15 2013]

Blogs

sort by: Date \| Relevance
Does Dendreon Still Have Potential? [Published Wall St. Cheat Sheet - May 14 2013] With shares of Dendreon Corp. ( NASDAQ:DNDN ) trading at around $3.91, is DNDN an OUTPERFORM, WAIT AND SEE or STAY AWAY? Let’s analyze the stock with the relevant sections of our CHEAT SHEET investing framework : C = Catalyst for the Stock’s Movement ...
Investors are Digesting These Healthcare Stock ... [Published Wall St. Cheat Sheet - May 12 2013] Optimer Pharmaceuticals, Inc. ( NASDAQ:OPTR ) had a loss and missed Wall Street’s expectations, AND came up short on beating the revenue expectation. Adjusted Earnings Per Share decreased to $-0.65 in the quarter versus EPS of $-0.23 in the year-earlier ...
Medivation Earnings: Here’s Why the Stock is Fa... [Published Wall St. Cheat Sheet - May 09 2013] Medivation, Inc. ( NASDAQ:MDVN ) had a loss and beat Wall Street’s expectations, AND beat the revenue expectation. The revenue beat is a positive sign to shareholders seeking high growth out of the company. Shares are down 1.05%.Markets are at 5-year ...
Medivation Earnings: Here’s Why the Stock is Fa... [Published Wall St. Cheat Sheet - May 09 2013] Medivation, Inc. ( NASDAQ:MDVN ) had a loss and beat Wall Street’s expectations, AND beat the revenue expectation. The revenue beat is a positive sign to shareholders seeking high growth out of the company. Shares are down 1.05%. Markets are at 5-year ...
Medivation Earnings: Your Sneak Peek to the Big... [Published Wall St. Cheat Sheet - May 09 2013] Medivation ( NASDAQ:MDVN ) will report earnings after markets close on Thursday, May 9th. Medivation Inc. acquires, develops, and sells or partners biomedical technologies in the early development stage of the research and development process. Here ...

Press Releases

sort by: Date \| Relevance
Medivation Names Stephen Kelsey Senior Vice Pre... [Published Marketwire - Breaking News Releases - May 13 2013]
Medivation Reports First Quarter Financial Resu... [Published Marketwire - Breaking News Releases - May 09 2013]
Medivation Announces Participation at Upcoming ... [Published Marketwire - Breaking News Releases - May 06 2013]
Surveyed Physicians Indicate that Xtandi is Pre... [Published PR Newswire: General Business - May 06 2013]
Medivation Elects Wendy L. Yarno to Board of Di... [Published Marketwire - Breaking News Releases - Apr 29 2013]